Skip to main content
MGNX
NASDAQ Life Sciences

Stockholders Approve 1.25 Million Share Increase for Equity Incentive Plan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$4.46
Mkt Cap
$283.492M
52W Low
$1.185
52W High
$4.635
52W Position info
276% above low
Off High info
3.8% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

MGNX has more than doubled off its 52-week low of $1.185.

Summary

MacroGenics stockholders approved an increase of 1.25 million shares for the company's equity incentive plan, representing nearly 2% potential dilution.


Key Events · Financing and Capital Events · MGNX

  • Equity Plan Share Increase Approved

    Stockholders approved an amendment to the 2023 Equity Incentive Plan, adding 1,250,000 shares for future issuance to employees and directors.

  • Potential Dilution

    This authorization represents a potential dilution of approximately 1.97% of the company's 63,560,068 outstanding common shares.

  • Routine Annual Meeting Approvals

    Other proposals, including the election of four Class I directors, ratification of Ernst & Young LLP as independent auditors, and an advisory vote on executive compensation, were also approved.


Analysis · MGNX · Life Sciences

MacroGenics stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the shares available for issuance by 1,250,000. This authorization represents a potential dilution of approximately 1.97% of current outstanding shares, which could create an overhang on the stock, especially as the company is trading near its 52-week high. While not an immediate offering, it adds to the pool of shares that can be issued for compensation.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MGNX was trading at $4.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283.5M. The 52-week trading range was $1.19 to $4.64. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MGNX - Latest Insights

MGNX
Sep 03, 2026, 4:39 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $4.25
Real-time Price: $4.00 info
Change: -$0.250 (-6%) info
Market Cap: $254.801M info
MGNX
Aug 14, 2026, 4:19 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.22
Real-time Price: $4.00 info
Change: -$0.220 (-5%) info
Market Cap: $254.801M info
MGNX
Aug 13, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.97
Real-time Price: $4.00 info
Change: +$0.030 (+0.76%) info
Market Cap: $254.801M info
MGNX
Aug 13, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.97
Real-time Price: $4.00 info
Change: +$0.030 (+0.76%) info
Market Cap: $254.801M info
MGNX
Jul 23, 2026, 5:12 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.06
Real-time Price: $4.00 info
Change: -$0.060 (-1%) info
Market Cap: $254.801M info